Sign In
Buy TOVX
$0.210
-0.0001 (-0.0476%)
At Close: Jul 31, 2026
Theriva Biologics Announces Reverse Stock Split
04:05pm, Friday, 16'th Aug 2024
ROCKVILLE, Md., Aug. 16, 2024 (GLOBE NEWSWIRE) -- Theriva Biologics, Inc. (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of hig
Theriva™ Biologics Receives Rare Pediatric Drug Designation by the U.S. FDA for VCN-01 for the Treatment of Retinoblastoma
08:15am, Wednesday, 31'st Jul 2024
ROCKVILLE, Md., July 31, 2024 (GLOBE NEWSWIRE) -- Theriva™ Biologics, Inc. (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related di
Theriva™ Biologics Announces Fast Track Designation Granted by the U.S. FDA for VCN-01 for the Treatment of Metastatic Pancreatic Cancer
08:15am, Thursday, 23'rd May 2024
ROCKVILLE, Md., May 23, 2024 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases
Theriva™ Biologics to Participate in the A.G.P. Virtual Healthcare Conference
08:00am, Tuesday, 14'th May 2024
ROCKVILLE, Md., May 14, 2024 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases
Theriva™ Biologics Reports First Quarter 2024 Operational Highlights and Financial Results
07:00am, Tuesday, 07'th May 2024
- Reported topline data from the investigator sponsored Phase 1 trial of intravitreal VCN-01 in pediatric patients with refractory retinoblastoma; trial results were determined to be positive by the s
ROCKVILLE, Md., April 25, 2024 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related disease
–Phase 1 trial in collaboration with Sant Joan de Déu-Barcelona Children's Hospital (SJD) determined to have a positive outcome by the study Monitoring Committee–
– Lead product candidate, VCN-01 in combination with liposomal irinotecan demonstrated enhanced anti-tumor effects in a human pancreatic mouse xenograft –
Theriva™ Biologics Announces Presentation at the American Society for Cell and Gene Therapy 27th Annual Meeting
08:00am, Monday, 08'th Apr 2024
ROCKVILLE, Md., April 08, 2024 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related disease
Theriva Biologics, Inc. (TOVX) Q4 2023 Earnings Call Transcript
12:01pm, Monday, 25'th Mar 2024
Theriva Biologics, Inc. (TOVX) Q4 2023 Earnings Call Transcript
Theriva™ Biologics Reports Full-Year 2023 Operational Highlights and Financial Results
07:30am, Monday, 25'th Mar 2024
– The independent data monitoring committee (IDMC) recommended the continuation of VIRAGE, the Phase 2b clinical trial of VCN-01 in combination with chemotherapy for metastatic Pancreatic Ductal Ade
Theriva™ Biologics to Host Conference Call and Webcast to Discuss Full Year 2023 Operational Highlights and Financial Results
08:00am, Tuesday, 19'th Mar 2024
ROCKVILLE, Md., March 19, 2024 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related disease
Theriva™ Biologics to Participate in the BIO-Europe Spring Conference
08:00am, Monday, 11'th Mar 2024
ROCKVILLE, Md., March 11, 2024 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related disease
The independent data monitoring committee (IDMC) recommended the continuation of VIRAGE with no safety concerns raised; VIRAGE remains on track to complete enrollment in the first half of 2024 The ind
Theriva Biologics to Participate in the B. Riley Securities Annual Oncology Conference
08:00am, Tuesday, 16'th Jan 2024
ROCKVILLE, Md., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Theriva Biologics, Inc. (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related disea
